Latest Breaking News On - பயோமெட் பள்ளத்தாக்கு கண்டுபிடிப்புகள் - Page 1 : comparemela.com

ESMO: DESTINY-Lung01 Demonstrates Trastuzumab Deruxtecan Benefit in NSCLC

ESMO: DESTINY-Lung01 Demonstrates Trastuzumab Deruxtecan Benefit in NSCLC
physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.

United statesSanta monicaRoche genentechPeggy peckDaiichi sankyoEdwardb garonBobt liGuardant healthEuropean society of medical oncologyEarly drug development serviceNational cancer centerBiosceptre internationalMemorial sloan kettering cancer centerEuropean societyMedical oncologyThoracic oncology

Mutant Gene-Targeted Immunotherapy Approach Developed

share: This news release, issued by Johns Hopkins Medicine, describes a novel targeted immunotherapy approach. This new approach employs bispecific antibodies to treat cancer by eliciting a Tcell response against mutated p53. The researchers used the Highly Automated Macromolecular Crystallography (AMX) and Frontier Microfocusing Macromolecular Crystallography (FMX) beamlines to characterize the molecular structure of the proteins. AMX and FMX are beamlines at the National Synchrotron Light Source II (NSLS-II) a U.S. Department of Energy (DOE) Office of Science User Facility at Brookhaven National Laboratory. NSLS-II offers a comprehensive suite of life science research capabilities. Johns Hopkins media contacts: Amy Mone, 410-614-2915, amone@jhmi.edu, or Valerie Mehl, 410-614-2916, mehlva@jhmi.edu. Brookhaven Lab media contacts: Cara Laasch, 631-344-8458, laasch@bnl.gov or Peter Genzer, 631-344-3174, genzer@bnl.gov.

United statesMichaelb murphyShibin zhouValerie mehlEmily hanNickolas papadopoulosMichael hwangEvangeline watsonKatharine wrightAstra zeneca medimmune amplimmuneKatharinem wrightYana liElizabeth cookPatricka brownGabriel ghiaurBristol myers squibb

Bispecific antibodies targeting mutant RAS neoantigens

Diabodies see the unseeable RAS oncogene mutations are common in various cancers, controlling their growth and survival. Targeting mutant RAS proteins with antibodies has been unsuccessful due to low surface expression, even when targeting mutant RAS peptides presented via HLA on the surface of cancer cells. Douglass et al. used phage display to generate single-chain variable fragments (scFvs) specific for mutant RAS peptide-HLA complexes. The authors tested various bispecific, T cell–engaging antibody formulations, finding that single-chain diabodies (scDbs) combining the aforementioned scFv with an anti-CD3 scFv were able to induce T cell activation and subsequent killing of tumor cells expressing mutant RAS peptide-HLA complexes. This scDb approach opens the door for antibody-based therapies against mutant neoantigens expressed at very low levels on the surface of cancer cells.

Rock springsUnited statesAstra zeneca medimmune amplimmuneUltramer oligosBristol myers squibbJohns hopkins universityCommonwealth fundBloomberg kimmel institute for cancer immunotherapyNational institute of arthritisDk ludwig fund for cancer researchComics incAssembly cloning kit new england biolabsTetramer production labFred hutchinson immune monitoring labJohns hopkins university animal careMolecular sciences

Mutant gene-targeted immunotherapy approach developed

Two of the three research studies led by Jacqueline Douglass, M.D., Ph.D. candidate at the Johns Hopkins University School of Medicine and Emily Han-Chung Hsiue, M.D., Ph.D., postdoctoral fellow at Johns Hopkins report on a precision medicine immunotherapy approach that specifically kills cancer cells by targeting mutant protein fragments presented as antigens on the cancer cell surface. Although common across cancer types, p53 mutations have not been successfully targeted with drugs. Genetic alterations in tumor suppressor genes often resulted in their functional inactivation. Traditional drugs are aimed at inhibiting proteins. Inhibiting an already inactivated tumor suppressor gene protein in cancer cells, therefore, is not a feasible approach, says Hsiue, lead author on the

United statesMichaelb murphyShibin zhouEmily hanNickolas papadopoulosMichael hwangEvangeline watsonKatharine wrightAstra zeneca medimmune amplimmuneKatharinem wrightYana liPatricka brownGabriel ghiaurBristol myers squibbBert vogelsteinKenneth kinzler